Compare NP & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | PBLS |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | N/A | 2026 |
| Metric | NP | PBLS |
|---|---|---|
| Price | $29.03 | $27.32 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $28.17 | N/A |
| AVG Volume (30 Days) | 664.7K | ★ 710.9K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.84 | N/A |
| Revenue Next Year | $15.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $25.56 |
| 52 Week High | $31.75 | $28.28 |
| Indicator | NP | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | N/A |
| Support Level | $24.09 | N/A |
| Resistance Level | $31.63 | N/A |
| Average True Range (ATR) | 1.26 | 0.00 |
| MACD | 0.37 | 0.00 |
| Stochastic Oscillator | 90.60 | 0.00 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.